"È­ÀÌÀÚ ¹é½Å, ±ä±Þ »ç¿ë ½Åû..À̸£¸é ¿¬³» ¹èÆ÷ °¡´É"

ÃÖ¾Ö¸® ±âÀÚ | ±â»çÀÔ·Â 2020/11/19 [10:25]

¡ã ¹Ì±¹ Á¦¾àȸ»ç È­ÀÌÀÚ°¡ ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(Äڷγª19) ¹é½Å 3»ó ÀÓ»ó¿¡¼­ 90% È¿°ú¸¦ È®ÀÎÇß´Ù°í ¾Ë·ÁÁø 10ÀÏ ¿ÀÀü ¼­¿ï Áß±¸ Çѱ¹È­ÀÌÀÚÁ¦¾à ¾ÕÀ» ÇÑ ½Ã¹ÎÀÌ °É¾î°¡°í ÀÖ´Ù. 2020.11.10.     ©´º½Ã½º

 

ºê·¹ÀÌÅ©´º½º ÃÖ¾Ö¸® ±âÀÚ= ¹Ì±¹ Á¦¾à¾÷ü È­ÀÌÀÚ¿Í µ¶ÀÏ ¹ÙÀÌ¿À¾ØÅ×Å©°¡ °øµ¿ °³¹ßÇÑ ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(Äڷγª19) ¹é½ÅÀÇ ±ä±Þ »ç¿ëÀÌ À̸£¸é ¿¬³» °¡´ÉÇÒ °ÍÀ̶õ Àü¸ÁÀÌ ³ª¿Â´Ù.

 

¹ÙÀÌ¿À¾ØÅ×Å©ÀÇ ¿ì±¸¸£ »çÈù ÃÖ°í°æ¿µÀÚ(CEO)´Â 18ÀÏ(ÇöÁö½Ã°£) CNN°úÀÇ ÀÎÅͺ信¼­ "¿À´Â 20ÀÏ ¹Ì±¹¿¡¼­ ¹é½Å ±ä±Þ »ç¿ëÀ» À§ÇÑ ¼­·ù¸¦ Á¦ÃâÇÒ ¿¹Á¤"À̶ó¸ç "°ËÅä°¡ ¾ó¸¶³ª »¡¸® ¿Ï·áµÇ´ÂÁö¿¡ µû¶ó 2020³â ¾È¿¡ ½ÂÀÎ ¶Ç´Â Á¶°ÇºÎ ½ÂÀÎÀ» ¹ÞÀ» ¼öµµ ÀÖ´Ù"°í ¹àÇû´Ù.

 

È­ÀÌÀÚ¿Í ¹ÙÀÌ¿À¿£Å×Å©´Â À̳¯ ¾Õ¼­ ¼º¸íÀ» ÅëÇØ Äڷγª19 ¹é½ÅÀÇ 3»ó ÀÓ»ó ½ÃÇè ÃÖÁ¾ °á°ú, 95% ¿¹¹æ È¿°ú°¡ ³ªÅ¸³µ´Ù°í ¹ßÇ¥Çß´Ù. ¹é½ÅÀº ƯÈ÷ 65¼¼ ÀÌ»ó °í·ÉÃþ¿¡¼­µµ 94% ÀÌ»ó ¿¹¹æ È¿°ú¸¦ º¸¿´´Ù°í ¾Ë·ÁÁ³´Ù.

 

¶ÇÇÑ È­ÀÌÀÚ¿Í ¹ÙÀÌ¿À¾ØÅ×Å©´Â ¹é½Å¿¡ °üÇÑ ½É°¢ÇÑ ¾ÈÀü ¿ì·Á°¡ ¾ø¾ú´Ù°í µ¡ºÙ¿´´Ù.

 

»çÈù CEO´Â "¿ì¸® ¸ñÇ¥´Â 2021³â ù 4~5°³¿ù µ¿¾È ¼ö¾ï°³ °¡·® °ø±ÞÇÏ´Â °Í"À̶ó¸ç "¸ðµç ÀÏÀÌ ÀߵŠ¸Å¿ì ü°èÀûÀÎ ¹é½Å °ø±ÞÀÌ ÀÌ·ïÁø´Ù¸é 2021³â ¿©¸§, ´Ê¾îµµ °Ü¿ï¿¡´Â Á¤»óÀûÀ¸·Î º¸³¾ ¼ö ÀÖ´Ù°í ÀÚ½ÅÇÑ´Ù"°í °­Á¶Çß´Ù.

 

´Ù¸¸ "¸ðµç Á¤ºÎ°¡ °¡À»¿¡ µé¾î¼­±â Àü Àα¸ÀÇ ³ôÀº ¹é½Å Á¢Á¾·üÀ» °®Ãâ ¼ö ÀÖµµ·Ï ÇØ¾ß ÇÑ´Ù"°í ´çºÎÇß´Ù.

 

´Ù¸¸ »çÈù CEO´Â ¹é½Å ¿î¹Ý ¹®Á¦¿¡ ´ëÇØ¼± ÇØ°áÃ¥À» ¸ð»öÇϰí ÀÖ´Ù°í Çß´Ù. ±×´Â "¹é½ÅÀ» ½Ç¿Â¿¡¼­µµ ÃâÇÏÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» ¿¬±¸Çϰí ÀÖ´Ù. °³¹ß°ú ¿¬±¸¸¦ µ¿½Ã¿¡ ÁøÇàÇϰí ÀÖ´Ù"°í ¼³¸íÇß´Ù.

 

È­ÀÌÀÚ¿Í ¹ÙÀÌ¿À¿£Å×Å©ÀÇ Äڷγª19 ¹é½ÅÀº ¿µÇÏ 70µµ ÀÌÇÏÀÇ ÃÊÀú¿Â »óÅ¿¡¼­ º¸°üÇØ¾ß ÇÑ´Ù´Â Á¡ ¶§¹®¿¡ º¸±ÞÀÌ ¾î·Á¿ï ¼ö ÀÖ´Ù´Â ¿ì·Á°¡ ³ª¿Â ¹Ù ÀÖ´Ù. 

 

*¾Æ·¡´Â À§ ±â»ç¸¦ ±¸±Û ¹ø¿ª±â·Î ¹ø¿ªÇÑ ¿µ¹® ±â»çÀÇ [Àü¹®]ÀÌ´Ù. [Below is the [full text] of an English article translated from the above article with Google Translate.]

 

"Pfizer vaccine can be distributed within the year if you apply for urgent use."

 

It is predicted that the emergency use of a novel coronavirus infection (Corona 19) vaccine jointly developed by US pharmaceutical company Pfizer and German Bio&Tech will be possible within this year.

 

In an interview with CNN on the 18th (local time), Bio&Tech's CEO Ugur Sahin said, "We will submit documents for urgent use of the vaccine in the US on the 20th." It may be approved or conditionally approved within 2020.¡±

 

Pfizer and Bioentech announced in a statement earlier this day that the final result of the phase 3 clinical trial of the COVID-19 vaccine showed 95% prevention effect. It is known that the vaccine was particularly effective in preventing more than 94% of the elderly over 65 years of age.

 

It also added that Pfizer and Bio&Tech had no serious safety concerns regarding the vaccine.

 

¡°Our goal is to supply hundreds of millions of units in the first four to five months of 2021,¡± said Sahin. Emphasized.

 

However, he said, "All governments must ensure that the population has a high vaccination rate before entering the fall."

 

However, CEO Sahin said he was looking for a solution to the vaccine delivery problem. "We are working on a way to ship vaccines even at room temperature. We are working on development and research at the same time," he explained.

 

There have been concerns that Pfizer and Bioentech's COVID-19 vaccine may be difficult to distribute because it must be stored at a cryogenic temperature below -70 degrees Celsius.

±â»çÁ¦º¸ ¹× º¸µµÀÚ·á 119@breaknews.com
¨Ï Çѱ¹¾ð·ÐÀÇ ¼¼´ë±³Ã¼ ºê·¹ÀÌÅ©´º½º / ¹«´ÜÀüÀç ¹× Àç¹èÆ÷±ÝÁö
 

ÀÌ ±â»ç¸¦ ÈÄ¿øÇÏ°í ½Í½À´Ï´Ù.

µ¶ÀÚ´ÔÀÇ ÀÛÀº ÀÀ¿øÀÌ Å« ÈûÀÌ µË´Ï´Ù.
ÈÄ¿ø±ÝÀº ÀÎÅÍ³Ý ½Å¹®»ç 'ºê·¹ÀÌÅ©´º½º' ¹ßÀü¿¡ ¾²¿©Áý´Ï´Ù.
´Ð³×ÀÓ ÆÐ½º¿öµå µµ¹è¹æÁö ¼ýÀÚ ÀÔ·Â
³»¿ë
±â»ç ³»¿ë°ú °ü·ÃÀÌ ¾ø´Â ±Û, ¿å¼³À» »ç¿ëÇÏ´Â µî ŸÀÎÀÇ ¸í¿¹¸¦ ÈѼÕÇÏ´Â ±ÛÀº °ü¸®ÀÚ¿¡ ÀÇÇØ ¿¹°í ¾øÀÌ ÀÓÀÇ »èÁ¦µÉ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇϽñ⠹ٶø´Ï´Ù.
 
±¤°í